Medexus Pharmaceuticals Inc. (MEDXF)

Medexus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is April - March.

Year	2023	2022	2021	2020	2019
Revenue	112.56	108.1	108.1	76.7	79.66
Revenue Growth (YoY)	4.13%	0%	40.93%	-3.71%	214.09%
Cost of Revenue	53.55	48.06	48.06	38.77	37.66
Gross Profit	59	60.04	60.04	37.93	42.01
Selling, General & Admin	44.67	48.25	48.25	44.03	36.17
Research & Development	1.6	2.94	2.94	5.87	4.6
Other Operating Expenses	0	0.35	0	0	0
Operating Expenses	46.27	51.55	51.55	50.3	41.27
Operating Income	12.73	7.61	7.61	-15	-1.38
Interest Income	0	0	0	0	0
Interest Expense	10.55	13.61	13.61	12.22	9.82
Other Expense / Income	2.07	-0.95	-0.95	-23.4	20.31
Pretax Income	0.11	-5.04	-5.04	-3.82	-31.5
Income Tax	0.32	-6.26	-6.26	-0.94	-3.24
Net Income	-0.21	1.22	1.22	-2.88	-28.26
Shares Outstanding (Basic)	22	20	19	15	14
Shares Outstanding (Diluted)	22	21	19	15	14
Shares Change	8.76%	5.50%	28.01%	5.83%	44.92%
EPS (Basic)	-0.01	0.06	0.06	-0.19	-1.97
EPS (Diluted)	-0.01	0.06	0.06	-0.19	-1.97
EPS Growth	-	-7.32%	-	-	-
Free Cash Flow	14.14	-1.81	-1.81	-8.89	-5.72
Free Cash Flow Per Share	0.63	-0.09	-0.09	-0.59	-0.40
Gross Margin	52.42%	55.54%	55.54%	49.45%	52.73%
Operating Margin	11.31%	7.04%	7.04%	-19.55%	-1.73%
Profit Margin	-0.19%	1.13%	1.13%	-3.75%	-35.48%
Free Cash Flow Margin	12.56%	-1.67%	-1.67%	-11.60%	-7.18%
Effective Tax Rate	301.89%	-	-	-	-
EBITDA	18.51	14.57	14.57	-6.23	6.71
EBITDA Margin	16.45%	13.48%	13.48%	-8.12%	8.43%
Depreciation & Amortization	5.78	6.08	6.08	6.15	5.98
EBIT	12.73	8.49	8.49	-12.38	0.73
EBIT Margin	11.31%	7.85%	7.85%	-16.14%	0.92%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.